Canada - Health Canada has advised of the availability of revised patient information for prophylactic use of the antimalarial, mefloquine (Apo-Mefloquine®).

The warnings and contraindications sections have been modified to inform of:

• rare events that may occur with the use of Apo-Mefloquine, including anxiety, paranoia, depression, hallucinations, and psychotic behaviour; as well as suicidal ideation and suicide, for which no causal relationship with the use of Apo-Mefloquine has been confirmed; and

• the contraindication of Apo-Mefloquine for malaria prophylaxis in patients with active depression or a history of psychiatric disturbance (including depression, generalized anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorder) or a history of convulsions.

Reference: Health Canada, 25 January 2005 at http://www.hc-sc.gc.ca